BrainStorm Cell Therapeutics Inc.’s CEO Issues Annual Letter to Shareholders

Published: Jan 23, 2013

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that its CEO, Dr. Adrian Harel, has issued an Annual Letter to Shareholders summarizing the company’s extremely significant developments of 2012:

Back to news